Pro Share Advisors LLC Avrobio, Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$0.75 - $1.33 $8,715 - $15,454	-11,620 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$1.29 - $4.04 $3,615 - $11,324	-2,803 Reduced 19.43%	11,620 $16,000
Q4 2021 Feb 08, 2022	BUY	$3.45 - $6.05 $865 - $1,518	251 Added 1.77%	14,423 $57,000
Q3 2021 Nov 12, 2021	SELL	$5.53 - $9.28 $15,174 - $25,464	-2,744 Reduced 16.22%	14,172 $79,000
Q2 2021 Aug 13, 2021	BUY	$7.84 - $12.6 $12,841 - $20,638	1,638 Added 10.72%	16,916 $150,000
Q1 2021 May 14, 2021	BUY	$10.54 - $19.3 $20,616 - $37,750	1,956 Added 14.68%	15,278 $194,000
Q4 2020 Feb 09, 2021	BUY	$12.79 - $17.1 $170,388 - $227,806	13,322 New	13,322 $186,000
Q4 2019 Feb 12, 2020	SELL	$13.05 - $21.88 $142,492 - $238,907	-10,919 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$14.12 - $23.44 $154,176 - $255,941	10,919 New	10,919 $154,000
Q2 2019 Aug 13, 2019	SELL	$13.21 - $27.29 $125,785 - $259,855	-9,522 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$12.46 - $22.05 $118,644 - $209,960	9,522 New	9,522 $210,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.